Overexpression of the Mammalian Target of Rapamycin A Novel Biomarker for Poor Survival in Resected Early Stage Non-small Cell Lung Cancer

被引:42
|
作者
Dhillon, Tony [1 ]
Mauri, Francesco A. [2 ]
Bellezza, Guido [3 ]
Cagini, Lucio [4 ]
Barbareschi, Mattia [5 ]
North, Bernard V. [6 ]
Seckl, Michael J. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Sect Mol Oncol & Lung Canc Res, CR UK Labs, London W12 0NN, England
[2] Univ London Imperial Coll Sci Technol & Med, Dept Histopathol, London W12 0NN, England
[3] Univ Perugia, Perugia Med Sch, Inst Pathol, I-06100 Perugia, Italy
[4] Univ Perugia, Perugia Med Sch, Dept Thorac Surg, Div Canc Res, I-06100 Perugia, Italy
[5] Santa Chiara Hosp, Lab Mol Pathol, Unit Surg Pathol, Trento, Italy
[6] Univ London Imperial Coll Sci Technol & Med, Stat Advisory Serv, London W12 0NN, England
关键词
Non-small cell lung cancer; Prognosis; Biomarker; mTOR; VINORELBINE PLUS CISPLATIN; BLOOD-VESSEL INVASION; ADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTOR; CANCER STATISTICS; ADENOCARCINOMA; PATHWAY; ERCC1; ACTIVATION; EXPRESSION;
D O I
10.1097/JTO.0b013e3181ce6604
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: The best hope of cure for patients with non-small cell lung cancer (NSCLC) is surgical resection. However, even in stage IA patients, 30% die within 5 years. Further improvements in survival require a biomarker(s), which defines the subset of these patients destined to do badly so that they could be targeted for additional therapies. Here, we investigate whether the immunohistochemical expression of a key kinase implicated in lung cancer biology, the mammalian target of rapamycin (mTOR) can predict survival outcome in patients with early stage resected NSCLC. Materials and Methods: One hundred thirty-four patients with resected early stage (IA-IIB) NSCLC were pathologically reviewed centrally before staining for mTOR. Multiple variables including age, sex, stage, angioinvasion, lymph node status, and mTOR staining were assessed by univariate and multivariate analyses. Results: Stage (p = 0.044), lymph node status (p = 0.049), angioinvasion (p = 0.017), and mTOR staining (p = 0.007) were significant univariate predictors of poor survival. However, only angioinvasion (p = 0.016) and mTOR staining (p = 0.046) remained significant after multivariate analysis. Moreover, mTOR staining was the only variable to predict poor outcome in patients who either had negative lymph nodes (p = 0.016) or were stage IA (p = 0.0016). Conclusions: The mTOR staining provides a new biomarker for poor outcome in early stage NSCLC and could enable resected stage IA patients to be selected for novel therapies possibly with an mTOR inhibitor.
引用
收藏
页码:314 / 319
页数:6
相关论文
共 50 条
  • [1] OVER-EXPRESSION OF THE MAMMALIAN TARGET OF RAPAMYCIN (MTOR): A NOVEL BIOMARKER FOR POOR SURVIVAL IN RESECTED EARLY STAGE NON-SMALL CELL LUNG CANCER
    Dhillon, T.
    Seckl, M.
    Mauri, F.
    Belleza, G.
    North, B.
    Cagini, L.
    Barbareschi, M.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S70 - S70
  • [2] Over-expression of the mammalian target of rapamycin (mTOR): a novel biomarker for poor survival in resected early stage non-small cell lung cancer
    Dhillon, Tony
    Mauri, Francesco
    Bellezza, Guido
    Cagini, Lucio
    North, Bernard
    Barbareschi, Mattia
    Seckl, Michael
    CANCER RESEARCH, 2009, 69
  • [3] Mortalin overexpression predicts poor prognosis in early stage of non-small cell lung cancer
    Sun, Jie
    Che, Shuan-Long
    Piao, Jun-Jie
    Xu, Ming
    Chen, Li-Yan
    Lin, Zhen-Hua
    TUMOR BIOLOGY, 2017, 39 (03)
  • [4] Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer
    Nie, Wei
    Xu, Mi-die
    Gan, Lu
    Huang, Hai
    Xiu, Qingyu
    Li, Bing
    LABORATORY INVESTIGATION, 2015, 95 (01) : 56 - 64
  • [5] A NOVEL COMPOSITE BIOMARKER PANEL FOR DETECTION OF EARLY STAGE NON-SMALL CELL LUNG CANCER
    Abraham, Aswin
    Bedard, Eric
    Joy, Anil Abraham
    Ghosh, Sunita
    Wang, Xiaoyu
    Lim, Andrew
    Shao, Dongyu
    Roa, Wilson
    RADIOTHERAPY AND ONCOLOGY, 2021, 163 : S30 - S30
  • [6] A NOVEL COMPOSITE BIOMARKER PANEL FOR DETECTION OF EARLY STAGE NON-SMALL CELL LUNG CANCER
    Bedard, Eric L. R.
    Abraham, Aswin G.
    Joy, Anil A.
    Ghosh, Sunita
    Wang, Xiaoyu
    Lim, Andrew
    Shao, Dongyu
    Loebenberg, Raimar
    Roa, Wilson H.
    CLINICAL AND INVESTIGATIVE MEDICINE, 2021, 44 (01): : E15 - E24
  • [7] Survival in untreated early stage non-small cell lung cancer
    Chadha, AS
    Ganti, AK
    Sohi, JS
    Sahmoun, AE
    Mehd, SA
    ANTICANCER RESEARCH, 2005, 25 (05) : 3517 - 3520
  • [8] Immunohistochemical evaluation of the mammalian target of rapamycin pathway in stage I non-small cell lung carcinoma
    Kim, H. R.
    Choi, C. M.
    Lee, J. C.
    Shin, E.
    Park, Y. S.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S148 - S148
  • [9] Sex and Age-Associated Survival Following Resected Early Stage Non-Small Cell Lung Cancer
    Gibson, A.
    D'Silva, A.
    Dean, M.
    Tudor, R.
    Elegbede, A.
    Otsuka, S.
    Bebb, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S619 - S620
  • [10] miR-7 methylation as a biomarker to predict poor survival in early-stage non-small cell lung cancer patients
    Rodriguez-Antolin, Carlos
    Felguera-Selas, Laura
    Pernia, Olga
    Vera, Olga
    Esteban, Isabel
    Losantos Garcia, Itsaso
    de Castro, Javier
    Rosas-Alonso, Rocio
    Ibanez de Caceres, Inmaculada
    CELL AND BIOSCIENCE, 2019, 9 (01):